1
|
Jeffrey SL, Brigham DA, Chawla SP, Federman N, Hall FL, Gordon EM. From Mendel to Gene Therapy. Anticancer Res 2023; 43:4257-4261. [PMID: 37772566 DOI: 10.21873/anticanres.16620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 09/06/2023] [Accepted: 09/11/2023] [Indexed: 09/30/2023]
Affiliation(s)
| | | | - Sant P Chawla
- Cancer Center of Southern California/Sarcoma Oncology Research Center, Santa Monica, CA, U.S.A
| | | | | | - Erlinda M Gordon
- Aveni Foundation, Santa Monica, CA, U.S.A.;
- Cancer Center of Southern California/Sarcoma Oncology Research Center, Santa Monica, CA, U.S.A
| |
Collapse
|
2
|
Chawla SP, Olevsky O, Iyengar G, Brigham DA, Omelchenko N, Thomas S, Suryamohan K, Foshag L, Hall FL, Gordon EM. Early-stage CCNG1+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a CCNG1 Inhibitor. Anticancer Res 2023; 43:2383-2391. [PMID: 37247916 DOI: 10.21873/anticanres.16406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 04/11/2023] [Accepted: 04/24/2023] [Indexed: 05/31/2023]
Abstract
Women with HR+HER2+ early-stage breast cancer are disadvantaged by the lack of clinical trials focused on women ≥70 years of age. In the past years, there has been increasing controversy on the use of toxic chemotherapy as standard of care treatment for early- stage HR+ HER2+ breast carcinoma in older women. With precision medicine coming of age, molecular profiling of tumors and circulating tumor DNA has identified target oncogenes that could be used in designing an optimal treatment for this group of women. This article reviews the current treatment of early-stage triple receptor positive breast cancer, the risks of chemotherapy in older women, and CCNG1, a novel biomarker in development for the use of DeltaRex-G, a CCNG1 inhibitor. Further, future perspectives for DeltaRex-G in older women with early stage CCNG1+ HR+ HER2+ breast cancer are discussed.
Collapse
Affiliation(s)
- Sant P Chawla
- Cancer Center of Southern California, Santa Monica, CA, U.S.A
| | - Olga Olevsky
- UCLA David Geffen School of Medicine, Santa Monica, CA, U.S.A
| | - Geeta Iyengar
- Medical Imaging Center of Southern California, Santa Monica, CA, U.S.A
| | - Don A Brigham
- Cancer Center of Southern California, Santa Monica, CA, U.S.A
- Aveni Foundation, Santa Monica, CA, U.S.A
| | | | - Sonu Thomas
- Cancer Center of Southern California, Santa Monica, CA, U.S.A
| | | | - Leland Foshag
- Saint John's Cancer Institute, Santa Monica, CA, U.S.A
| | | | - Erlinda M Gordon
- Cancer Center of Southern California, Santa Monica, CA, U.S.A.;
- Aveni Foundation, Santa Monica, CA, U.S.A
| |
Collapse
|
3
|
Chawla SP, Tellez WA, Chomoyan H, Valencia C, Ahari A, Omelchenko N, Makrievski S, Brigham DA, Chua-Alcala V, Quon D, Moradkhani A, Gordon EM. Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311). Front Oncol 2023; 13:1116937. [PMID: 37234994 PMCID: PMC10206273 DOI: 10.3389/fonc.2023.1116937] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Accepted: 03/31/2023] [Indexed: 05/28/2023] Open
Abstract
Background Intratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin and nivolumab may have synergistic effects in advanced sarcomas. Patients and methods This phase 2 trial was conducted from May 30, 2019 to January 31, 2022. Endpoints: Primary: Progression free survival rate at month 12. Secondary: Best overall response, progression free survival rate at 6 and 9 months, overall survival rate at 6, 9, and 12 months, incidence of conversion of an unresectable tumor to a resectable tumor, and incidence of adverse events. Eligible patients had to be ≥ 18 years of age, have advanced histologically proven sarcoma, at least 1 previous chemotherapy regimen, and at least one accessible tumor for intratumoral injection. Treatment: Trabectedin intravenously (1.2 mg/m2 q3 weeks), nivolumab intravenously (3 mg/kg q2 weeks), and intratumoral talimogene laherparepvec (1x108 plaque forming units/ml q2 weeks). Results Median time of follow-up: 15.2 months. Efficacy analysis: Thirty-nine patients who had completed at least one treatment cycle and had a follow-up computerized tomography were evaluable for efficacy analysis. Median number of prior therapies: 4 (range 1-11). Progression free survival rate at month 12, 36.7%. Confirmed Best Overall Response by Response Evaluation Criteria in Solid Tumors v1.1 = 3 partial responses, 30 stable disease, 6 progressive disease. Best Overall Response Rate, 7.7%, Disease Control Rate, 84.6%; median progression free survival, 7.8 (95% Confidence Intervals: 4.1-13.1) months; 6-, 9-, 12-month progression free survival rates, 54.5%/45.9%/36.7%; median overall survival 19.3 (95% Confidence Intervals: 12.8 -.) months; 6-, 9- and 12-month overall survival rate, 86.9%/73.3%/73.3%. One patient had a complete surgical resection. Fifty percent of patients had a ≥ grade 3 treatment related adverse events which included anemia (6%), thrombocytopenia (6%), neutropenia (4%), increased alanine transaminase (4%), decreased left ventricular ejection fraction (4%), dehydration (4%), hyponatremia (4%). Conclusions Taken together these data suggest that the TNT regimen is effective and safe for advanced previously treated sarcomas, and is worth being further studied in a randomized phase 3 trial as first- or second- line treatment for patients with advanced sarcomas.
Collapse
Affiliation(s)
- Sant P. Chawla
- Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States
| | - Walter Andree Tellez
- Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States
| | - Hripsime Chomoyan
- Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States
| | - Chrysler Valencia
- Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States
| | - Amir Ahari
- Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States
| | - Nadezhda Omelchenko
- Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States
| | - Stefan Makrievski
- Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States
| | - Don A. Brigham
- Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States
- Gene and Cell Therapy, Aveni Foundation, Santa Monica, CA, United States
| | - Victoria Chua-Alcala
- Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States
| | - Doris Quon
- Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States
| | - Ania Moradkhani
- Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States
| | - Erlinda M. Gordon
- Medical Oncology, Sarcoma Oncology Research Center, Santa Monica, CA, United States
- Gene and Cell Therapy, Aveni Foundation, Santa Monica, CA, United States
| |
Collapse
|
4
|
Rakerd B, Brigham DA, Clemens LG. A microcomputer-based system for recording and analyzing behavioral data regarding the sexual activity of male rodents. Physiol Behav 1985; 35:999-1001. [PMID: 3841612 DOI: 10.1016/0031-9384(85)90272-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
A microcomputer (TRS-80 Model 4P) based system has been developed to aid in the collection and analysis of behavioral data regarding sexual activity in male rodents. Its capabilities include the recording of events, the online calculation of frequency and latency measures, the monitoring of temporal intervals as demanded by experimental protocols, and the prompting of experimenter activities at prescribed times.
Collapse
|